LBF20207PG47: Difference between revisions
No edit summary |
No edit summary |
||
| (9 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
|LipidBank=XPR1790 | |LipidBank=XPR1790 | ||
|LipidMaps=- | |LipidMaps=- | ||
|SysName=9alpha,11alpha- | |SysName=(9alpha,11alpha) -Dihydroxy-15-oxo- (8beta) -prosta- (cis-5,trans-13) -dien-1-oic acid | ||
|Common Name=&&8-iso-15-keto Prostaglandin | |Common Name=&&8-iso-15-keto Prostaglandin F_2 alpha&&(9alpha,11alpha) -Dihydroxy-15-oxo- (8beta) -prosta- (5Z,13E) -dien-1-oic acid&& | ||
|Source= | |Source= | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=In vasoconstriction studies, 8-iso-15-keto PGF2 | |Biological Activity=In vasoconstriction studies, 8-iso-15-keto PGF2 alpha has been reported as a member of vasoconstrictor on the rat isolated thoracic aorta through TP receptor.[[Reference:Cracowski_JL:Camus_L:Durand_T:Devillier_P:Guy_A:Hardy_G:Stanke-Labesque_F:Rossi_JC:Bessard_G:,J. Cardiovasc. Pharmacol.,2002,39,396|{{RelationTable/GetFirstAuthor|Reference:Cracowski_JL:Camus_L:Durand_T:Devillier_P:Guy_A:Hardy_G:Stanke-Labesque_F:Rossi_JC:Bessard_G:,J. Cardiovasc. Pharmacol.,2002,39,396}}]] | ||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} | ||
Latest revision as of 17:37, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1790 |
| LipidMaps | - |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20207PG47 |
| 8-iso-15-keto Prostaglandin F2α | |
|---|---|
| |
| Structural Information | |
| (9α,11α) -Dihydroxy-15-oxo- (8β) -prosta- (cis-5,trans-13) -dien-1-oic acid | |
| |
| Formula | C20H32O5 |
| Exact Mass | 352.224974134 |
| Average Mass | 352.46508 |
| SMILES | C(CCC(=O)C=C[C@H]([C@@H]1CC=CCCCC(O)=O)[C@@H](C[C@@H]1O)O)CC |
| Physicochemical Information | |
| In vasoconstriction studies, 8-iso-15-keto PGF2 alpha has been reported as a member of vasoconstrictor on the rat isolated thoracic aorta through TP receptor. Cracowski_JL et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
